PTAB

Increased Adoption of Artificial Intelligence Across the Healthcare Industry Driving Strong Market Growth

Retrieved on: 
Wednesday, March 27, 2024
PWD, African Americans, Conditional sentence, Patient, Big data, Intellectual property, Lidar, Artificial intelligence, Certification, AMD, Risk, Sony, PALM, 3D, NIH, Treatment, Culture, Safety, OTCQB, CE marking, Weather, SSS, Prevalence, Radiology, Intelligence, Family, PLTR, Depth perception, Triage, News, Historical trauma, Cancer, AI, MDR, MPH, Butterfly, Health equity, Diagnosis, Arrhythmia, Health, Butterfly network, Growth, Patent, Perception, SNM, PTAB, AIP, FAAFP, FRCS, Medical device

In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.

Key Points: 
  • In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.
  • Mordor Intelligence continued: “The increased prevalence of cancer and the high burden of other chronic diseases are, in turn, increasing the demand for accurate diagnosis and treatment.
  • This is likely to increase the adoption of AI for early diagnosis purposes, ultimately boosting the market growth.
  • The use of artificial intelligence in the North American healthcare market is being driven by the increasing use of advanced technology in healthcare systems, the growth in funding of AI-based startups, the rising burden of chronic diseases in the country, the growing need to reduce healthcare costs, and the implementation of big data in healthcare.

Alzheon Announces that United States Federal Circuit Affirmed Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharmaceutical Technology Co., Ltd.’s Patent on Isotopically Enriched Forms of ALZ-801/Valiltramiprosate

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Professional Services, Health, Patent Law, Pharmaceutical, Neurology, Research, Genetics, Legal, Science, Clinical Trials, Comment, Patent, Patient, NDA, PTAB, Federal Circuit Court, Doctor of Philosophy, IPR, Prodrug, Rule 34, Pharmaceutical industry

The decision was affirmed without discussion by the Federal Circuit Court (Case No.

Key Points: 
  • The decision was affirmed without discussion by the Federal Circuit Court (Case No.
  • In 2020, Alzheon petitioned the Patent Trial and Appeal Board (PTAB) of the U.S. Patent Office (USPTO) to institute an Inter-Parties Review (IPR) of Risen’s U.S. Patent No.
  • Risen appealed the PTAB’s decision to the United States Court of Appeals for the Federal Circuit.
  • “Alzheon is pleased that the U.S. Federal Circuit affirmed the Patent Trial and Appeal Board’s decision to invalidate all claims of Risen’s patent.

Novarad Wins Patent Litigation with Medivis Over Augmented Reality Navigation System

Retrieved on: 
Wednesday, March 20, 2024
Anatomy, VISAR, 3D, PTAB, Surgeon, Patent, Data, FDA, Physician, Medicine

Salt Lake City, Utah, March 20, 2024 (GLOBE NEWSWIRE) -- Novarad Corporation, a leading provider of augmented reality surgical navigation, is thrilled to announce a significant legal victory in a recent patent case.

Key Points: 
  • Salt Lake City, Utah, March 20, 2024 (GLOBE NEWSWIRE) -- Novarad Corporation, a leading provider of augmented reality surgical navigation, is thrilled to announce a significant legal victory in a recent patent case.
  • The decision, reached in Novarad Corp. v. Medivis, Inc., is poised to have far-reaching consequences for Novarad and its groundbreaking augmented reality product, VisAR.
  • In the case of Novarad Corp. v. Medivis, Inc., the Patent Trial and Appeal Board (PTAB) rendered a decision in favor of Novarad; dismissing a petition to invalidate Novarad’s patent.
  • "With this legal victory behind us, we are more determined than ever to continue advancing the frontiers of augmented reality technology in medicine."

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
Research, PRINT, SVB, Patient, Pulmonary hypertension, Sale, NDA, PTAB, Orthostatic hypertension, Promotion, Safety, Security, PAH, FDA, Food, Cryptocurrency

ET

Key Points: 
  • ET
    MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the full year ended December 31, 2023.
  • ET to discuss the 2023 financial results and provide a corporate update.
  • In December 2023, the previous ruling by the Patent Trial and Appeal Board (PTAB) that all of the claims in U.S. Patent No.
  • The year ended December 31, 2023 included a $2.3 million loss on extinguishment of debt related to repayment of the A&R SVB LSA in January 2023.

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Health, Neurology, Legal, Finance, General Health, Pharmaceutical, PGR, Plasma, Medication, Patent, Patient, Ganaxolone, PTAB, IPR, Marinus, Pharmacology, Inter partes review, Patent office, Therapy, Epilepsy, Status epilepticus, Pharmaceutical industry

This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).

Key Points: 
  • This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).
  • “Over the past two decades, Marinus has invested more than $100 million into our ganaxolone development programs in SE,” stated Dr. Scott Braunstein, Chairman and CEO of Marinus.
  • We believe this Ovid challenge is without merit and is an unfortunate distraction to the important work we do at Marinus.
  • In response to Marinus’ request for PGR, Ovid abandoned 23 of the 31 claims in its patent.

Axonics Provides Update on Inter Partes Review Proceedings

Retrieved on: 
Thursday, March 21, 2024
Neurology, Legal, Medical Supplies, Patent Law, Health, Medical Devices, Health Technology, Professional Services, Medtronic, Patent, Patient, Intellectual property, PTAB, Pharmaceutical industry

Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting.
  • 8,626,314 (“the ‘314 patent”) and 8,036,756 (“the ‘756 patent”).
  • Medtronic has asserted these patents, which expired in 2021 and 2022, against Axonics’ proprietary tined lead design.
  • Axonics plans to seek review of the PTAB’s finding that the remaining claims were not unpatentable.

Vizgen Announces Denial of 10x Genomics’ Petition for Inter Partes Review of Vizgen-Licensed Patent Currently Asserted Against 10x’s Xenium Platform

Retrieved on: 
Wednesday, March 13, 2024
Medical Devices, Infectious Diseases, Neurology, Genetics, Health Technology, Biometrics, Biotechnology, Pharmaceutical, Health, Oncology, Genomics, Science, Patent, District court, PTAB, IPR, Harvard University, Invention, Inter partes review

This is the latest in a series of rulings against 10x in its aggressive attempts to weaponize patents to dominate the field through baseless litigation.

Key Points: 
  • This is the latest in a series of rulings against 10x in its aggressive attempts to weaponize patents to dominate the field through baseless litigation.
  • 22-595-MFK, the parallel case in the U.S. District Court for the District of Delaware, Vizgen has asserted a number of counterclaims including the assertion that the Xenium platform infringes certain claims of the ‘303 Patent.
  • It is very encouraging to see our patent prevail on the basis of its technical and scientific contributions to the field.
  • We believe the PTAB’s decision underscores the importance and value of Vizgen’s inventions,” said Terry Lo, CEO of Vizgen.

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Retrieved on: 
Thursday, March 21, 2024
MRI, Patent, District court, SNM, PTAB, Complaint, ITC, Intellectual property

DUBLIN, March 21, 2024  /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

Key Points: 
  • DUBLIN, March 21, 2024 /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies.
  • Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.
  • Medtronic will now ask the federal court in the Central District of California, where Medtronic's patent infringement lawsuit is pending, to lift its stay on the lawsuit and proceed to trial on the five valid and affirmed patents so Medtronic can present its case in front of a jury.
  • "We respect the intellectual property of innovators, and our patent system exists to benefit society by encouraging the kind of innovation that Medtronic invests in.

With Capital Raise, Vizgen Commits to Its Long-term Success and Defense Against Baseless Anti-Competitive Legal Actions

Retrieved on: 
Friday, March 8, 2024
Oncology, Health, Infectious Diseases, Genetics, Research, Science, Biotechnology, Chemistry, Growth, Harvard University, Partner, PTAB, Patent, IP, Genomics

These measures come in response to unlawful monopolistic conduct by 10x Genomics and Harvard University, Vizgen’s own licensor—including baseless patent litigation in the U.S. and Europe.

Key Points: 
  • These measures come in response to unlawful monopolistic conduct by 10x Genomics and Harvard University, Vizgen’s own licensor—including baseless patent litigation in the U.S. and Europe.
  • Despite being the target of anticompetitive legal claims, Vizgen remains fully committed to its mission of providing the industry’s best tools for single-cell spatial biology and driving discoveries aimed at improving human health.
  • With the new funding, Vizgen continues to invest in the development of its groundbreaking technologies, ensuring a long-term commitment to support its customers.
  • Responsible enforcement of IP is important to our industry but not to the point of weaponizing patent litigation through baseless claims.

Endologix Initiates Percutaneous Transmural Arterial Bypass (PTAB)1 Post-Market Study

Retrieved on: 
Thursday, February 29, 2024
Health, Surgery, Cardiology, Medical Devices, SVS, Woman, TASC, PAD, Moyamoya disease, Society, Vascular disease, SFA, PTAB, Patient, Pharmaceutical industry

The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).

Key Points: 
  • The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).
  • The PTAB1 Post-Market Study evaluates the DETOUR System's performance in patients with very long (TASC D) SFA lesions.
  • The study plans to enroll up to 450 subjects, with a focus on including at least 200 women and also features an imaging sub study.
  • “The initiation of the PTAB1 Post-Market Study represents a pivotal moment in our ongoing commitment to advance the treatment of complex peripheral arterial disease.